Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Newell

Showing results (451-460 of 519) with videos related to

Pageof 52
Sort By:
Organic & Biomolecular Chemistry|May 8, 2010
Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitorsFrancesco Marchetti, Céline Cano, Nicola J Curtin, et al.
Cancer Research|May 19, 2006
Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441Yan Zhao, Huw D Thomas, Michael A Batey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cellsNicola J Curtin, Lan-Zhen Wang, Anthie Yiakouvaki, et al.
British Journal of Cancer|August 26, 2016
Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinomaSari F Alhasan, Beate Haugk, Laura F Ogle, et al.
Molecular Cancer Therapeutics|June 11, 2009
Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicityHuw D Thomas, Kappusamy Saravanan, Lan-Zhen Wang, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 12, 2004
Effect of cell cycle inhibition on Cisplatin-induced cytotoxicityMelissa L Fishel, David R Newell, Roger J Griffin, et al.
British Journal of Cancer|June 13, 2014
Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastomaL Chen, Y Zhao, G C Halliday, et al.
Journal of Medicinal Chemistry|September 17, 2004
Resistance-modifying agents. 11.(1) Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to alpha1-acid glycoproteinNicola J Curtin, Hannah C Barlow, Karen J Bowman, et al.
British Journal of Cancer|August 17, 2016
Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancerGary Beale, Emma J Haagensen, Huw D Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumorsI Rafi, A V Boddy, J A Calvete, et al.
Pageof 52

Showing results (451-460 of 519) with videos related to

Sort By:
Pageof 52
Organic & Biomolecular Chemistry|May 8, 2010
Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitorsFrancesco Marchetti, Céline Cano, Nicola J Curtin, et al.
Cancer Research|May 19, 2006
Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441Yan Zhao, Huw D Thomas, Michael A Batey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cellsNicola J Curtin, Lan-Zhen Wang, Anthie Yiakouvaki, et al.
British Journal of Cancer|August 26, 2016
Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinomaSari F Alhasan, Beate Haugk, Laura F Ogle, et al.
Molecular Cancer Therapeutics|June 11, 2009
Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicityHuw D Thomas, Kappusamy Saravanan, Lan-Zhen Wang, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 12, 2004
Effect of cell cycle inhibition on Cisplatin-induced cytotoxicityMelissa L Fishel, David R Newell, Roger J Griffin, et al.
British Journal of Cancer|June 13, 2014
Structurally diverse MDM2-p53 antagonists act as modulators of MDR-1 function in neuroblastomaL Chen, Y Zhao, G C Halliday, et al.
Journal of Medicinal Chemistry|September 17, 2004
Resistance-modifying agents. 11.(1) Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to alpha1-acid glycoproteinNicola J Curtin, Hannah C Barlow, Karen J Bowman, et al.
British Journal of Cancer|August 17, 2016
Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancerGary Beale, Emma J Haagensen, Huw D Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 1998
Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given by prolonged administration in patients with solid tumorsI Rafi, A V Boddy, J A Calvete, et al.
Pageof 52